aTyr Pharma begins Resolaris Phase Ib/II trial to treat early onset FSHD

aTyr Pharma has started a Phase Ib/II trial of Resolaris for patients with early onset facioscapulohumeral muscular dystrophy (FSHD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news